(919) 237-4897 info@t3dtherapeutics.com

RESEARCH TRIANGLE PARK, N.C.Aug. 27, 2020 /PRNewswire/ — T3D Therapeutics, a clinical stage drug development company engaged in the development of T3D-959, a new orally administered treatment for Alzheimer’s disease (AD), announced today that it has received a $740,000 grant from the Alzheimer’s Association Part the Cloud-Gates Partnership Grant Program in support of clinical trial biomarker studies.  These biomarker studies are an integral part of the upcoming Phase 2 clinical study of T3D-959, a novel, metabolic-focused AD drug treatment.

Read Full Press Release Here